Who are Abrocitinib Suspension F1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leqselvi, Cibinqo, Cibinqo, ABROCITINIB, Jyseleca, Tofacitinib plus mesalamine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abrocitinib-suspension-f1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Abrocitinib Suspension F1 — Competitive Intelligence Brief

Abrocitinib Suspension F1 (abrocitinib-suspension-f1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor. Area: Immunology.

marketed JAK inhibitor JAK1 Immunology Live · refreshed every 30 min

Target snapshot

Abrocitinib Suspension F1 (abrocitinib-suspension-f1) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abrocitinib Suspension F1 TARGET	abrocitinib-suspension-f1	Pfizer	marketed	JAK inhibitor	JAK1
Leqselvi	DEURUXOLITINIB	Sun Pharm Inds Inc	marketed		JAK1, JAK2, TYK2	2024-01-01
Cibinqo	abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
Cibinqo	Abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
ABROCITINIB	ABROCITINIB		marketed	Janus Kinase Inhibitor [EPC]	JAK1	2021-01-01
Jyseleca	FILGOTINIB	Gilead Sciences Ireland UC	marketed		Tyrosine-protein kinase JAK1	2020-01-01
Tofacitinib plus mesalamine	Tofacitinib plus mesalamine	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	JAK inhibitor plus aminosalicylate	JAK1/JAK3 (tofacitinib); unclear specific target for mesalamine (likely prostaglandin-related)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

Pfizer · 19 drugs in this class
Aclaris Therapeutics, Inc. · 2 drugs in this class
Beijing Friendship Hospital · 2 drugs in this class
Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
CAGE Bio Inc. · 1 drug in this class
CTI BioPharma · 1 drug in this class
Celgene · 1 drug in this class
Fred Hutchinson Cancer Center · 1 drug in this class
LEO Pharma · 1 drug in this class
McMaster University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abrocitinib Suspension F1 — Competitive Intelligence Brief. https://druglandscape.com/ci/abrocitinib-suspension-f1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab